EP3691670A4 - Methods and compositions for efficient delivery through multiple bio barriers - Google Patents

Methods and compositions for efficient delivery through multiple bio barriers Download PDF

Info

Publication number
EP3691670A4
EP3691670A4 EP18864985.9A EP18864985A EP3691670A4 EP 3691670 A4 EP3691670 A4 EP 3691670A4 EP 18864985 A EP18864985 A EP 18864985A EP 3691670 A4 EP3691670 A4 EP 3691670A4
Authority
EP
European Patent Office
Prior art keywords
barriers
compositions
methods
efficient delivery
multiple bio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18864985.9A
Other languages
German (de)
French (fr)
Other versions
EP3691670A1 (en
Inventor
Eggehard Holler
Julia Y. Ljubimova
Keith L. Black
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of EP3691670A1 publication Critical patent/EP3691670A1/en
Publication of EP3691670A4 publication Critical patent/EP3691670A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43572—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from bees
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Insects & Arthropods (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP18864985.9A 2017-10-02 2018-10-02 Methods and compositions for efficient delivery through multiple bio barriers Withdrawn EP3691670A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762566813P 2017-10-02 2017-10-02
PCT/US2018/053873 WO2019070645A1 (en) 2017-10-02 2018-10-02 Methods and compositions for efficient delivery through multiple bio barriers

Publications (2)

Publication Number Publication Date
EP3691670A1 EP3691670A1 (en) 2020-08-12
EP3691670A4 true EP3691670A4 (en) 2021-08-04

Family

ID=65995287

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18864985.9A Withdrawn EP3691670A4 (en) 2017-10-02 2018-10-02 Methods and compositions for efficient delivery through multiple bio barriers

Country Status (4)

Country Link
EP (1) EP3691670A4 (en)
CN (1) CN111182913A (en)
RU (1) RU2020114744A (en)
WO (1) WO2019070645A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022156531A1 (en) * 2021-01-19 2022-07-28 中国人民解放军军事科学院军事医学研究院 Dynein binding peptide capable of permeating through biological barrier, and use thereof
WO2023094810A1 (en) * 2021-11-24 2023-06-01 Ucl Business Ltd Polymersomes for clearance of amyloid beta and/or tau proteins
CN115025249B (en) * 2022-05-12 2024-02-20 深圳市第二人民医院(深圳市转化医学研究院) Targeting probe and preparation method and application thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US20080227736A1 (en) * 2004-06-03 2008-09-18 Regents Of The University Of California, Targeting Pseudotyped Retroviral Vectors
US9365634B2 (en) * 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
JP5219168B2 (en) * 2008-03-13 2013-06-26 天津医科大学 Β-sheet destruction peptide for prevention and / or treatment of Alzheimer's disease
US8785371B2 (en) * 2009-12-10 2014-07-22 Cedars-Sinai Medical Center Drug delivery of temozolomide for systemic based treatment of cancer
US9623041B2 (en) * 2010-12-30 2017-04-18 Cedars-Sinai Medical Center Polymalic acid-based nanobiopolymer compositions
CN103582497A (en) * 2011-04-06 2014-02-12 西奈医疗中心 Polymalic acid based nanoconjugates for imaging
EP2723350B1 (en) * 2011-06-24 2017-11-01 Université de Genève New uses of nanog inhibitors and related methods
DE102012108598A1 (en) * 2012-09-14 2014-04-10 Forschungszentrum Jülich GmbH New D3-D enantiomeric peptides derived from D3 and their use
CN102716495B (en) * 2012-06-20 2014-04-23 中国人民解放军第四军医大学 Multifunctional poly(malic acid) carried drug for targeting treatment of tumors
PT3016671T (en) * 2013-07-04 2021-12-02 Univ Barcelona Actively transported and protease-resistant peptides as bbb shuttles and shuttle-cargo constructs
US20190060479A1 (en) * 2016-03-04 2019-02-28 Cedars-Sinai Medical Center Polymalic acid based nanoimmunoconjugates and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Correction for Ding et al., Inhibition of brain tumor growth by intravenous poly(L-malic) acid nanobioconjugate with pH-dependent drug release", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 107, no. 45, 27 October 2010 (2010-10-27), pages 19603 - 19603, XP055098887, ISSN: 0027-8424, DOI: 10.1073/pnas.1015385107 *
ISRAEL LIRON L. ET AL: "A Combination of Tri-Leucine and Angiopep-2 Drives a Polyanionic Polymalic Acid Nanodrug Platform Across the Blood-Brain Barrier", ACS NANO, 26 February 2019 (2019-02-26), US, XP055811026, ISSN: 1936-0851, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641102/pdf/nihms-1054603.pdf> DOI: 10.1021/acsnano.8b06437 *
See also references of WO2019070645A1 *

Also Published As

Publication number Publication date
EP3691670A1 (en) 2020-08-12
RU2020114744A (en) 2021-11-09
CN111182913A (en) 2020-05-19
WO2019070645A1 (en) 2019-04-11

Similar Documents

Publication Publication Date Title
EP3694489A4 (en) Methods and compositions for topical delivery
EP3355954A4 (en) Delivery methods and compositions
EP3523437A4 (en) Oligonucleotide compositions and methods thereof
EP3664815A4 (en) Oligonucleotide compositions and methods thereof
EP3463386A4 (en) Oligonucleotides, compositions and methods thereof
EP3411414A4 (en) Compositions and methods for targeted cytokine delivery
EP3694530A4 (en) Oligonucleotide compositions and methods thereof
EP3452596A4 (en) Oligonucleotide compositions and methods thereof
EP3325017A4 (en) Oligonucleotide compositions and methods thereof
EP3528732A4 (en) Method and device for enhanced composition delivery
EP3436482A4 (en) Antibodies, pharmaceutical compositions and methods
EP3300507A4 (en) Gene delivery methods and compositions
EP3328377A4 (en) Compositions and methods for immuno-oncology therapies
EP3283435A4 (en) Composition, particulate materials and methods for making particulate materials.
EP3288387A4 (en) Microbial compositions and methods for bioprotection
EP3353306A4 (en) Conjugated antisense compounds and their use
EP3197279A4 (en) Antimicrobial compositions and methods
EP3353305A4 (en) Conjugated antisense compounds and their use
EP3233192A4 (en) Compositions and methods for targeted cytokine delivery
EP3189074A4 (en) Compositions and methods for treating and preventing inflammation
EP3442543A4 (en) Compositions and methods for neuralgenesis
EP3377486A4 (en) Insecticidal compositions and methods
EP3435983A4 (en) Compositions and methods for selective gi tract delivery
EP3253389A4 (en) Apilimod compositions and methods for using same
EP3386594A4 (en) Compositions and methods for treating drug-tolerant glioblastoma

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200430

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20210706

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/00 20060101AFI20210630BHEP

Ipc: C07K 7/00 20060101ALI20210630BHEP

Ipc: C07K 7/06 20060101ALI20210630BHEP

Ipc: C07K 7/08 20060101ALI20210630BHEP

Ipc: C07K 14/435 20060101ALI20210630BHEP

Ipc: A61K 31/713 20060101ALI20210630BHEP

Ipc: A61K 38/08 20190101ALI20210630BHEP

Ipc: A61K 47/59 20170101ALI20210630BHEP

Ipc: A61K 47/64 20170101ALI20210630BHEP

Ipc: A61P 35/00 20060101ALI20210630BHEP

Ipc: A61P 25/00 20060101ALI20210630BHEP

Ipc: C07K 5/083 20060101ALI20210630BHEP

Ipc: C07K 14/47 20060101ALI20210630BHEP

Ipc: C07K 14/81 20060101ALI20210630BHEP

Ipc: C07K 17/08 20060101ALI20210630BHEP

Ipc: C07K 19/00 20060101ALI20210630BHEP

Ipc: C07K 5/087 20060101ALI20210630BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220203